Pro-Dex, Inc. — Form 10-Q Summary
Period: Fiscal third quarter and first nine months ended March 31, 2015; comparative periods ended March 31, 2014. The request metadata says “2014 Q3,” but the filing itself reports fiscal 2015 Q3. Financial statement amounts are in thousands of dollars except per-share data.
Business context and reporting period
Pro-Dex designs and manufactures products for medical, dental, industrial, research and government markets, and provides engineering services. During the period it acquired Huber Precision and Fineline Molds, expanding into machined parts and plastic injection molds. Its business remained concentrated in medical-device products and a major customer.
Financial performance and condition
| Metric | Three months ended March 31, 2015 | Nine months ended March 31, 2015 | Comparable 2014 period |
|---|---|---|---|
| Net sales | $3.922 million | $9.310 million | $2.404 million; $7.599 million |
| Gross profit / margin | $1.045 million / 27% | $2.569 million / 28% | $0.540 million / 22%; $2.035 million / 27% |
| Operating loss | $390,000 | $973,000 | $438,000; $798,000 |
| Net loss | $76,000 | $438,000 | $385,000; $512,000 |
| Net loss per share | $0.02 | $0.10 | $0.12; $0.15 |
| Operating cash flow | $438,000 used in the nine-month period | $343,000 used |
Third-quarter sales rose 63% year over year; nine-month sales rose 23%. Management attributed growth principally to higher shipments to its largest customer, partly reflecting that the prior-year period included a five-month suspension of shipments. Gross margin improved, helped by increased production volume and manufacturing-cost absorption. Operating expenses increased 47% in the quarter and 25% year to date.
Net results included realized investment gains of $395,000 for the quarter and $455,000 year to date. The company liquidated its public-equity investment portfolio to support working capital. Excluding that gain, the reported operating losses and continuing-operation losses underscore that core operations remained unprofitable.
At March 31, 2015, cash was $1.475 million, working capital was $6.212 million, and current assets and liabilities were $9.995 million and $3.783 million, respectively. Total assets were $12.615 million; total liabilities were $4.213 million. The balance sheet reported $100,000 of acquisition-related note payable ($24,000 current) and no material bank borrowing. Cash fell $1.713 million from June 30, 2014. Nine-month investing cash use was $1.080 million, including $1.236 million for notes receivable, $865,000 for acquisitions and $242,000 for capital expenditures. The company repurchased 69,773 shares for $154,000 during the nine months.
Material changes and management commentary
- Huber Precision was acquired for $209,000 in December 2014; Fineline Molds was acquired for $757,000 in February 2015, including a $100,000 seller note. The acquisitions were intended to diversify offerings and broaden the customer base.
- Inventory increased to $3.444 million from $2.600 million, which management linked to preparation for launches of two new products. The company reported a $9.7 million backlog and approximately $400,000 of third-quarter shipments related to a surgical-handpiece collaboration.
- The largest customer accounted for 48% of quarterly sales and 54% of nine-month sales; it represented 37% of gross receivables at quarter-end. Management is pursuing new products, engineering services and acquisition integration, but gave no quantified revenue or earnings guidance.
- Management said existing cash and potential third-party financing under evaluation were expected to fund operations for the next 12 months, while cautioning that financing might not be available on acceptable terms.
Risks, contingencies and unusual items
- Riverside notes: Pro-Dex purchased defaulted notes for $1.2 million, carried at $1.236 million at quarter-end, on nonaccrual status and secured by real estate and business assets. It agreed to forbear enforcement until July 31, 2015 and could advance up to $200,000 under a revolving facility. Its maximum investment at risk was estimated at $1.405 million. The company concluded it was not the VIE’s primary beneficiary at March 31. A May 7, 2015 deed and settlement agreement provided for transfer of property in exchange for recharacterizing $1.0 million of debt as non-recourse; accounting treatment was still under evaluation.
- Customer and execution risks: Significant reliance on one customer, successful new-product launches, integration of acquired businesses and the ability to diversify revenue remain important uncertainties. Management noted risks from competition, technological change and recovering the Riverside investment.
- Warranty and contract costs: The warranty reserve rose to $393,000 from $237,000 at June 30, 2014. The company also recorded estimated losses on certain development-service contracts.
- Taxes and legal matters: A $3.9 million valuation allowance was maintained against deferred tax assets; unrecognized tax benefits were $398,000. The company reported no legal proceedings it considered material and no material changes to previously disclosed risk factors.
- Controls and leadership: The CEO and CFO resigned during the quarter and successors were appointed. Management concluded disclosure controls were effective and reported no other material internal-control changes.
Important facts for investors to verify
- Whether the May 2015 Riverside settlement transfers the collateral as expected, how it affects the notes’ carrying value and VIE assessment, and whether further advances or losses occur.
- Whether the two product launches, reported backlog and new-customer opportunities convert into shipments and cash receipts.
- Whether customer concentration declines and the acquisitions and engineering-services division contribute sustainable margins.
- Whether working-capital needs can be funded after the investment portfolio liquidation, given operating cash use and the company’s stated reliance on potential financing.
- Whether warranty accruals, development-contract loss estimates and deferred tax asset assumptions remain appropriate as results develop.